News for Regeneron Pharmaceuticals, Inc. (REGN)

The major U.S. stock indexes showed resilience on Thursday, June 19, 2025, as markets reopened following the Juneteenth holiday. The S&P 500 edged up 0.2%

TTAM Commits to Comply with Company's Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to

**media[654541]**

U.S. stock futures are pointing to a mixed open on Wednesday, June 11, 2025, as investors digest the latest developments in U.S.-China trade negotiations and

The stock market opened with cautious optimism on Tuesday, June 10, 2025, as investors closely monitored ongoing US-China trade negotiations while awaiting

U.S. stock futures are pointing to a slightly higher open on Tuesday, June 10, 2025, as market news today centers on ongoing trade negotiations between the

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Regeneron Pharmaceuticals, Inc.

On June 2, 2025, Citigroup analyst Geoff Meacham maintained his 'Buy' rating for Regeneron Pharmaceuticals (REGN), while also lowering the price target from $70

On June 2, 2025, BMO Capital analyst Evan David Seigerman made significant adjustments to their assessment of Regeneron Pharmaceuticals (REGN), a leading biotec

Key Highlights: Regeneron Pharmaceuticals (REGN) reports promising interim results in obesity treatment trials. Analysts forecast a potential upside of 5

Regeneron Pharmaceuticals (REGN) is in the spotlight following a notable update from Morgan Stanley. On June 2, 2025, the investment firm adjusted its price tar

Summary Regeneron Pharmaceuticals Inc (REGN) has announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited to acquire exclu

Regeneron (REGN) experienced a setback when its partner, Sanofi, announced mixed outcomes from the Phase 3 trials of itepekimab, a treatment targeting COPD. Thi

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China P

Regeneron Pharmaceuticals (REGN) has entered into a strategic agreement with Hansoh Pharmaceuticals to acquire exclusive rights for the development and commerci

Summary Regeneron Pharmaceuticals Inc (REGN) has released interim results from its Phase 2 COURAGE trial, which explores the efficacy of combining semaglutide w

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a key report revealed softening inflation.